- Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
- Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
- Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
- Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
- Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
- Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
- Pharvaris Announces Extraordinary Meeting of Shareholders
- Pharvaris to Present at the WSAAI Annual Meeting 2024
- Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
More ▼
Key statistics
On Friday, Pharvaris NV (PHVS:NSQ) closed at 23.35, -29.24% below its 52-week high of 33.00, set on Feb 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.56 |
---|---|
High | 25.44 |
Low | 22.20 |
Bid | 9.60 |
Offer | 38.40 |
Previous close | 22.77 |
Average volume | 113.10k |
---|---|
Shares outstanding | 53.82m |
Free float | 32.74m |
P/E (TTM) | -- |
Market cap | 1.23bn USD |
EPS (TTM) | -2.71 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼